Literature DB >> 28868937

Ameliorative effect of nicotine exposure on insulin resistance is accompanied by decreased cardiac glycogen synthase kinase-3 and plasminogen activator inhibitor-1 during oral oestrogen-progestin therapy.

Olugbenga S Michael1,2,3, Lawrence A Olatunji1,2.   

Abstract

CONTEXT: Cigarette smoking is considered to be a major risk factor for the development of diabetes and cardiovascular disease. Oestrogen-progestin combined oral contraceptive (COC) use has been associated with adverse cardiometabolic events.
OBJECTIVE: We hypothesized that nicotine would ameliorate insulin resistance (IR) that is accompanied by decreased cardiac glycogen synthase kinase-3 (GSK-3) and plasminogen activator inhibitor-1 (PAI-1).
METHODS: Female Wistar rats received (po) low-(0.1 mg/kg) or high-nicotine (1.0 mg/kg) with or without COC containing 5.0 µg levonorgestrel plus 1.0 µg ethinylestradiol daily for 8 weeks.
RESULTS: Data showed that COC treatment or nicotine exposure led to IR, glucose deregulation, atherogenic dyslipidemia, increased corticosterone, aldosterone, cardiac and circulating GSK-3 values and PAI-1. However, these effects with the exception of corticosterone and aldosterone were ameliorated in COC + nicotine-exposed rats.
CONCLUSION: Amelioration of IR induced by COC treatment is accompanied by decreased circulating PAI-1, cardiac PAI-1 and GSK-3 instead of circulating aldosterone and corticosterone.

Entities:  

Keywords:  Combined oral contraceptives; glycogen synthase kinase-3; insulin resistance; nicotine; pancreatic β-cell function

Mesh:

Substances:

Year:  2017        PMID: 28868937     DOI: 10.1080/13813455.2017.1369549

Source DB:  PubMed          Journal:  Arch Physiol Biochem        ISSN: 1381-3455            Impact factor:   4.076


  5 in total

1.  Oral ethinylestradiol-levonorgestrel attenuates cardiac glycogen and triglyceride accumulation in high fructose female rats by suppressing pyruvate dehydrogenase kinase-4.

Authors:  Kehinde Samuel Olaniyi; Lawrence Aderemi Olatunji
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-01       Impact factor: 3.000

2.  Combined but not single treatment with ethinylestradiol/levonorgestrel and spironolactone reduces plasminogen activator inhibitor-1 in insulin-resistant ovariectomised rats.

Authors:  Adeyanju Oluwaseun Aremu; Dibia Chinaza Lilian; Soladoye Ayodele Olufemi; Olatunji Lawrence Aderemi
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2019 Oct-Dec       Impact factor: 1.636

Review 3.  Plasminogen activator inhibitor 1 and gestational diabetes: the causal relationship.

Authors:  Gaber El-Saber Batiha; Hayder M Al-Kuraishy; Thabat J Al-Maiahy; Ali K Al-Buhadily; Hebatallah M Saad; Ali I Al-Gareeb; Jesus Simal-Gandara
Journal:  Diabetol Metab Syndr       Date:  2022-09-08       Impact factor: 5.395

4.  Suppression of Adenosine Deaminase and Xanthine Oxidase Activities by Mineralocorticoid and Glucocorticoid Receptor Blockades Restores Renal Antioxidative Barrier in Oral Contraceptive-Treated Dam.

Authors:  Olufunto O Badmus; Emmanuel D Areola; Eleojo Benjamin; Matthew A Obekpa; Tolulope E Adegoke; Oluwatobi E Elijah; Aminu Imam; Olayemi J Olajide; Lawrence A Olatunji
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021-05-18       Impact factor: 1.636

5.  Sexual function and metabolic/hormonal changes in women using long-term hormonal and non-hormonal contraceptives: a pilot study.

Authors:  Igor Fernando de Aquino Moreira; Maria Passos Bianchini; Gabrielle Rodrigues Campos Moreira; Alessandra Maciel Almeida; Bruno Almeida Rezende
Journal:  BMC Womens Health       Date:  2020-10-27       Impact factor: 2.809

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.